Lundbeck Q3 2019 Financial Results
Foliglurax - an interesting new pipeline asset currently in PoC testing in
Parkinson's patients
*
*
*
*
32
32
Increase activity of a specific
glutamatergic target (mGluR4)
Symptomatic treatment of OFF-time
in Parkinson's and levodopa induced
dyskinesia
Strong IP
Global rights to foliglurax and full
control of asset
Phase II started in July 2017
* Two active arms + placebo (BID)
* ~165 patients (Europe)
* Change in awake OFF time based
on subject diary entries
Levodopa-induced
dyskinesia
Dyskinesia
ON time without dyskinesia
OFF time
Disease progression in patients with motor fluctuations
Dyskinesia
With
ON time without dyskinesia
addition of
foliglurax
(illustrative)
OFF time
1) NCT03162874
Disease progression in patients with motor fluctuations
Modified based on: Jankovic, Mov. Disorder 2005,
Motor complications of
levodopa
*
PD-LID is the most important unmet
medical need after disease
modification in Parkinson's²)
*
PD-LID affects -50% after 5-10
years increasing to -90% after 10-
*
15 years of L-DOPA therapy
170-200,000 patients in the U.S.
with PD-LID
Once established, PD-LID is difficult
to treat
PD-LID: Parkinson's Disease - Levodopa-Induced Dyskinesia
2) Datamonitor
LundbeckView entire presentation